| Literature DB >> 34348116 |
Elizabeth Miller1, Pauline A Waight2, Nick J Andrews3, Kelsey McOwat4, Kevin E Brown5, Höschler Katja6, Samreen Ijaz7, Mary Sinnathamby8, Hannah Cuthbertson9, Bassam Hallis10, Vaishnavi Parimalanathan11, Simon de Lusignan12, Jamie Lopez-Bernal13.
Abstract
OBJECTIVES: To measure secondary attack rates (SARs) in prospectively followed household contacts of paediatric and adult cases of SARS-CoV-2 infection in England.Entities:
Keywords: SARS-CoV-2 transmission; households; secondary attack rates by age
Year: 2021 PMID: 34348116 PMCID: PMC8325949 DOI: 10.1016/j.jinf.2021.07.037
Source DB: PubMed Journal: J Infect ISSN: 0163-4453 Impact factor: 6.072
Fig. 1Flow diagram of study population and post-recruitment exclusions.
Demographic and clinical features of the 181 index cases and 452 household contacts.
| Feature | Level | INDEX CASES ( | CONTACTS ( |
| Household size (total number of participating individuals) | 2 | 43 (24%) | 43 (10%) |
| 3 | 42 (23%) | 84 (19%) | |
| 4 | 65 (36%) | 193 (43%) | |
| 5 | 25 (14%) | 99 (22%) | |
| 6 | 4 (2%) | 20 (4%) | |
| ≥7 | 2 (1%) | 13 (2%) | |
| Gender | Female | 103 (57%) | 226 (50%) |
| Male | 78 (43%) | 226 (50%) | |
| Age group (years) | 0 to 10 | 37 (20%) | 93 (21%) |
| 11 to 18 | 55 (30%) | 80 (18%) | |
| 19 to 54 | 66 (37%) | 233 (51%) | |
| >=55 | 23 (13%) | 46 (10%) | |
| Any Comorbidity | No | 149 (82%) | 380 (84%) |
| Yes | 32 (18%) | 72 (16%) | |
| Type of Comorbidity | Medicated asthma | 17 (9%) | 43 (10%) |
| (Subjects may have >1) | Diabetes | 7 (4%) | 11 (2%) |
| Respiratory disease | 1 (1%) | 5 (1%) | |
| Neurological condition | 5 (3%) | 4 (1%) | |
| Heart disease | 6 (3%) | 6 (1%) | |
| Liver/kidney disease | 2 (1%) | 6 (1%) | |
| Immune compromised | 3 (2%) | 6 (1%) | |
| Malignancy | 1 (<1%) | 7 (2%) |
Secondary attack rates in contacts with a serological or oral fluid outcome. Analysis excludes 55 households with a prior or co-primary case and 22 asymptomatic antibody positive PCR negative contacts whose timing of infection could not be established.
| Factor | Level | n/N | % (95% CI) | P-value | |
| All | 75/248 | 33% (25–40) | |||
| Gender of contact | Female | 34/120 | 31% (22–39) | 0.516 | |
| Male | 41/128 | 34% (25–43) | |||
| Age of contact (years) | 0to10 | 7/40 | 16% (4–28) | 0.119 | |
| 11to18 | 11/40 | 33% (19–48) | |||
| 19to54 | 49/145 | 36% (28–45) | |||
| >=55 | 8/23 | 32% (14–51) | |||
| Gender of index case | Female | 42/139 | 33% (23–42) | 0.998 | |
| Male | 33/109 | 32% (22–43) | |||
| Age of index case | 0to10 | 14/61 | 25% (12–38) | 0.346 | |
| 11to18 | 26/94 | 30% (19–41) | |||
| 19to54 | 26/73 | 36% (23–49) | |||
| >=55 | 9/20 | 49% (24–73) | |||
| Index case self isolating | No | 8/29 | 30% (10–51) | 0.844 | |
| Yes | 66/217 | 33% (25–40) | |||
| Household size | 2 | 15/28 | 54% (35–72) | 0.009 | |
| 3 | 18/52 | 35% (20–50) | (trend) | ||
| 4 | 29/110 | 28% (18–38) | |||
| 5+ | 13/58 | 21% (8–35) | |||
| Minimum Ct value in index case | 35–40 | 12/38 | 31% (13–48) | 0.44 | |
| 30–34 | 13/40 | 33% (17–50) | (trend) | ||
| 25–29 | 13/36 | 38% (20–56) | |||
| 20–24 | 13/43 | 33% (16–51) | |||
| <20 | 6/14 | 45% (16–74) | |||
| Index case with loss taste/ smell | No | 20/77 | 28% (16–40) | 0.262 | |
| Yes | 53/153 | 37% (28–46) | |||
| 1Index case with respiratory symptoms | No | 2/38 | 6% (0–14) | 0.003 | |
| Yes | 73/210 | 37% (29–45) | |||
| 2Index case with gastro symptoms | No | 29/103 | 30% (19–40) | 0.526 | |
| Yes | 46/145 | 34% (25–44) | |||
| 3Index case with systemic symptoms | No | 2/22 | 10% (0–24) | 0.048 | |
| Yes | 73/226 | 35% (27–42) | |||
1. Cough
shortness of breath
sore throat
runny nose
2. Nausea and diarrhoea
3. Fever
headache
fatigue
muscle/body pain.
Clinical features in 121 prospectively followed infected contacts (prior and co-primary infected contacts excluded).
| Feature | Level | n/N | % (95% CI) | P-value |
| Proportion reporting one or more solicited symptoms | 94/121 | 78% | ||
| Proportion with one or more solicited symptoms by age (years) | 0 to10 | 13/18 | 72% | 0.440 |
| 11to18 | 15/21 | 71% | ||
| 19to54 | 57/69 | 83% | ||
| >=55 | 9/13 | 69% | ||
| Proportion with symptoms by presence of co-morbidity | None | 73/96 | 76% | 0.590 |
| Any | 21/25 | 84% | ||
| Proportion symptomatic with respiratory symptoms | 0 to10 | 9/13 | 69% | |
| 11to18 | 15/15 | 100% | ||
| 19to54 | 53/57 | 93% | ||
| >=55 | 9/9 | 100% | ||
| Proportion symptomatic with loss of taste/smell | 0 to10 | 3/12* | 25% | |
| 11to18 | 4/15 | 27% | ||
| 19to54 | 39/57 | 68% | ||
| >=55 | 6/9 | 67% | ||
| Proportion symptomatic with systemic symptoms | 0 to10 | 13/13 | 109 4 0% | |
| 11to18 | 14/15 | 93% | ||
| 19to54 | 56/57 | 98% | ||
| >=55 | 9/9 | 100% | ||
| Mean number of symptoms | 0 to10 | 4.4 | ||
| 11to18 | 5.8 | |||
| 19to54 | 7.4 | |||
| >=55 | 7.4 | |||
*symptom not known for one child.
Fig. 2Serial intervals within households: days between symptom onset in index and contact.
Proportion of nasal swabs PCR positive, and mean Ct values in PCR positive swabs by time since onset of symptoms in infected contacts and index cases; first and second nasal swab combined.
| interval from symptom onset | PCR Positive | Total tested | % PCR Positive (95% CI) | mean Ct |
| −7 to −1 | 2 | 11 | 18.2% (2.3–51.8) | 23.22 |
| 0 to 2 | 11 | 21 | 52.4% (29.8–74.3) | 27.34 |
| 3 to 6 | 35 | 56 | 62.5% (48.5–75.1) | 27.33 |
| 7 to 9 | 45 | 85 | 52.9% (41.8–63.9) | 30.02 |
| 10 to 13 | 37 | 128 | 28.9% (21.2–37.6) | 32.95 |
| 14 to 20 | 27 | 197 | 13.7% (9.2–19.3) | 34.88 |
| 21 to 27 | 4 | 71 | 5.6% (1.6–13.8) | 36.35 |
| 28+ | 3 | 34 | 8.8% (1.9–23.7) | 36.51 |
| Total | 164 | 603 | 27.2% (23.7–3u0.9) | 30.94 |
*95% CI does not account for some individuals contributing two samples.
Sensitivity (% Infected with symptom) and positive predictive value of symptoms in contacts with a serological or oral fluid outcome, includes prior and co-primary cases.
| Reported symptoms | A: Infected ( | B: Uninfected ( | Positive predictive value A/ |
| Fever + cough + loss taste/smell | 42 (23%) | 3 (1%) | 93% |
| At least 2 of the above | 90 (50%) | 15 (7%) | 86% |
| At least one of the above | 132 (73%) | 64 (32%) | 67% |
| Other solicited symptom* | 21 (11.7%) | 43 (21%) | 33% |
| Any solicited symptom | 153 (85%) | 107 (53%) | 59% |
*Includes runny nose, sore throat, shortness of breath, nausea, diarrhoea, fatigue, muscle/body pain, headache.